i、Bone marrow-derived mesenchymal stem cells
Ischemia-tolerant human mesenchymal stem cells (ithMSCs) have higher tolerability, activity, and post-homing repair capacity under conditions of hypoxic ischemia. Upon homing to injured body parts, ithMSCs can secret various cytokines, chemokines, anti-inflammatory factors and growth factors to rescue high-risk cells, protect healthy cells, as well as create conditions optimal to proliferation and repair of endogenous cells.
ii、Neural stem cells
Ischemia-tolerant human neural stem cells (ithNSCs) are predominantly undifferentiated pluripotent nerve cells. NSCs manufactured by Stemedica are able to differentiate into neurons, astrocytes and oligodendrocytes, and survive under hypoxic conditions, thus offering better therapies for ischemic diseases. NSCs administered separately or in combination with MSCs have demonstrated excellent efficacy in clinical trials for treatment of neurological conditions including Alzheimer’s disease, spinal cord injuries, cerebral stroke and others.
iii、Stem cell factors
Jiuzhitang Maker’s stem cells factors are manufactured with processes different from those for common stem cell byproducts. We culture clinical-grade stem cells only for manufacture of stem cell factors in order to achieve higher concentrations and activity. Patented preservation technology makes it possible to store solid-state stem cell factors in room temperature for 3 years without losing biological activities.
iv、Stem cell-derived exosomes
Originating from cells, exosomes are disc-like microvesicles holding cellular contents with a diameter of around 30-100 nm. Several cells can secret exosomes under normal and pathological states, which mainly come from multi-vesicular bodies created through invagination of cytolysosomes. Exosomes are considered as specifically secreted vesicles, and its role in cell communication is closely linked to source cells.
Exosomes secreted by MSCs have functions similar to those of MSCs such as acceleration of tissue healing, inhibition of inflammations, promotion of angiogenesis, etc., which makes them a good candidate for use in modulating tissue regeneration. Compared with MSCs, MSC-derived exosomes are smaller, less complex, and easier to manufacture and store. More importantly, it’s easier to formulate exosomes into drugs as they are not live cells. Using a GMP-compliant and large-scale manufacturing platform, Jiuzhitang Maker will be producing pharmaceutical grade MSC-derived exosomes with proven safety and activity, and work hard to formulate exosomes into drugs.